Peds-PLAN, pediatric precision laboratory advanced neuroblastoma therapy: Molecular guided therapy for high risk neuroblastoma at diagnosis

2023-08-24T14:03:08-04:00April 24th, 2018|

Jacqeline Kraveka, Valerie Brown, William Ferguson, Genevieve Bergendahl, William Roberts, Jessica Foley, Deanna Mitchell, Javier Oesterheld, Michael Isakoff, Kathleen Neville, Randal Wada, Jawhar Rawwas, Gina Hanna, Abhinav Beeravally Nagulapally, Jeffrey Bond, Jeffrey Trent, William Hendricks, Sarah Byron, Giselle Sholler. Peds-PLAN, pediatric precision laboratory advanced neuroblastoma therapy: Molecular guided therapy for high risk neuroblastoma at diagnosis, American [...]

The MDM2 inhibitor CGM097 synergizes with the BET inhibitor OTX015 to induce cell death in neuroblastoma cells

2023-08-24T14:05:36-04:00April 18th, 2018|

Tyler Maser, Joseph Zagorski, Austin Goodyke, Elizabeth VanSickle, Jeffrey Bond, Giselle Sholler. The MDM2 inhibitor CGM097 synergizes with the BET inhibitor OTX015 to induce cell death in neuroblastoma cells, American Association for Cancer Research (AACR), April 2018

Genomic and high-throughput pharmacologic correlative analysis of 10 diffuse intrinsic pontine glioma

2023-08-24T14:06:32-04:00March 24th, 2018|

Elizabeth VanSickle, Abhinav Nagulapally, Delvano Capobianco, Jeff Bond, Rick Neubig, Tom Dexheimer, Giselle Sholler. Genomic and high-throughput pharmacologic correlative analysis of 10 diffuse intrinsic pontine glioma, 2nd Pediatric Precision Oncology Conference 2018, Scottsdale, AZ (Poster presentation)

Exceptional clinical response to molecular guided therapy in a patient with progressive lymphoepithelioma-like thymic carcinoma

2023-08-24T14:07:15-04:00February 24th, 2018|

M. Ghanim, Giselle Sholler, M. Hudspeth, L. Donahoo, W. Rieter, Geneveive Bergendahl, Gina Hanna, William Hendricks, Sara Byron, Abhinav Nagulapally, Jeff Bond, Jeff Trent, Jackie Kraveka. Exceptional clinical response to molecular guided therapy in a patient with progressive lymphoepithelioma-like thymic carcinoma, 2nd Pediatric Precision Oncology Conference 2018, Scottsdale, AZ (Poster presentation)

Genomic analysis and precision therapy for high risk neuroblastoma at diagnosis and relapse

2023-08-24T14:08:03-04:00February 20th, 2018|

Jackie Kraveka, William Ferguson, Al Cornelius, Deanna Mitchell, William Roberts, Javier Oesterheld, Jeff Bond, Abhinav Nagulapally, William Hendricks, Sara Byron, Jeff Trent, Giselle Sholler. Genomic analysis and precision therapy for high risk neuroblastoma at diagnosis and relapse, 2nd Pediatric Precision Oncology Conference 2018, Scottsdale, AZ (Poster presentation)

Genomic analysis and precision therapy for recurrent and resistant osteosarcoma

2023-08-24T14:08:49-04:00February 12th, 2018|

William Ferguson, Al Cornelius, Jackie Kraveka, William Roberts, Javier Oesterheld, Abhinav Nagulapally, William Hendricks, Sara Byron, Jeff Trent, Giselle Sholler. Genomic analysis and precision therapy for recurrent and resistant osteosarcoma, 2nd Pediatric Precision Oncology Conference 2018, Scottsdale, AZ (Poster presentation)

Genomic analysis and precision therapy for recurrent and resistant ewing’s sarcoma

2023-08-24T14:09:29-04:00February 9th, 2018|

Al Cornelius, Jackie Kraveka, Bill Ferguson, Deanna Mitchell, William Roberts, Javier Oesterheld, Abhinav Nagulapally, William Hendricks, Sara Byron, Jeff Trent, Giselle Sholler. Genomic analysis and precision therapy for recurrent and resistant ewing’s sarcoma, 2nd Pediatric Precision Oncology Conference 2018, Scottsdale, AZ (Poster presentation)

DFMO Maintains Remission in Relapsed/Refractory High Risk Neuroblastoma

2023-08-24T16:44:17-04:00September 24th, 2017|

Giselle Sholler, William Ferguson, Genevieve Bergendahl, Jeffrey Bond, Kathleen Neville, Don Eslin, Valerie I. Brown, William Roberts, Randy Wada, Javier Oesterheld, Deanna Mitchell, Jessica Foley,Peter Zage, Jawhar Rawwas, Susan F. Sencer,Jacqueline Kraveka. DFMO Maintains Remission in Relapsed/Refractory High Risk Neuroblastoma, The American Society of Pediatric Hematology/Oncology Annual Meeting 2017, Montreal, Quebec, Canada

DFMO synergizes with BET inhibitors targeting ODC and MYCN to impede neuroblastoma cell proliferation and tumor initiation

2023-08-24T16:53:03-04:00April 24th, 2017|

Sarah DeCou, Ping Zhao, Tracey Avequin, Abhinav Nagulapally, Jeffrey Bond, Giselle Saulnier Sholler. DFMO synergizes with BET inhibitors targeting ODC and MYCN to impede neuroblastoma cell proliferation and tumor initiation, American Association for Cancer Research (AACR) Annual Meeting, April, 2017, Washington, DC

Go to Top